Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aurinia Pharmaceuticals stock | $12.48

Learn how to easily invest in Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 294 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aurinia Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AUPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aurinia Pharmaceuticals stock price (NASDAQ: AUPH)

Use our graph to track the performance of AUPH stocks over time.

Aurinia Pharmaceuticals shares at a glance

Information last updated 2021-07-28.
Latest market close$12.48
52-week range$9.72 - $18.60
50-day moving average $12.50
200-day moving average $13.39
Wall St. target price$11.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.70

Buy Aurinia Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aurinia Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aurinia Pharmaceuticals price performance over time

Historical closes compared with the close of $12.48 from 2021-06-04

1 week (2021-07-23) N/A
1 month (2021-07-02) -1.96%
3 months (2021-05-03) -0.64%
6 months (2021-01-30) N/A
1 year (2020-07-30) N/A
2 years (2019-07-30) N/A
3 years (2018-07-30) N/A
5 years (2016-07-30) N/A

Aurinia Pharmaceuticals financials

Revenue TTM $51 million
Gross profit TTM $-209,000
Return on assets TTM -21.82%
Return on equity TTM -40.13%
Profit margin -249.26%
Book value $2.89
Market capitalisation $1.8 billion

TTM: trailing 12 months

Shorting Aurinia Pharmaceuticals shares

There are currently 13.4 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 4% up from 12.8 million last month.

There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.

Aurinia Pharmaceuticals's "short interest ratio" (SIR)

Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 2.9 million). Aurinia Pharmaceuticals's SIR currently stands at 4.58. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 4580 shares are currently held short.

However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1086% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 109 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.

Find out more about how you can short Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals share dividends

We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.

Have Aurinia Pharmaceuticals's shares ever split?

Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.

Aurinia Pharmaceuticals share price volatility

Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $9.72 up to $18.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.3393. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).

Aurinia Pharmaceuticals overview

Aurinia Pharmaceuticals Inc. , a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company is headquartered in Victoria, Canada. .

Frequently asked questions

What percentage of Aurinia Pharmaceuticals is owned by insiders or institutions?
Currently 8.022% of Aurinia Pharmaceuticals shares are held by insiders and 47.536% by institutions.
How many people work for Aurinia Pharmaceuticals?
Latest data suggests 294 work at Aurinia Pharmaceuticals.
When does the fiscal year end for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals's fiscal year ends in December.
Where is Aurinia Pharmaceuticals based?
Aurinia Pharmaceuticals's address is: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8
What is Aurinia Pharmaceuticals's ISIN number?
Aurinia Pharmaceuticals's international securities identification number is: CA05156V1022
What is Aurinia Pharmaceuticals's CUSIP number?
Aurinia Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05156V102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site